Lumacaftor/ivacaftor initiation in two liver transplantation patients under tacrolimus and antifungal azoles

被引：18

作者：

Chouchane, Ikrame ^{[1
]}

Stremler-Lebel, Nathalie ^{[2
]}

Reix, Philippe ^{[3
,4
]}

机构：

[1] Ctr Hosp Univ, Hop Dupuytren, Serv Pediat, Hop Mere Enfant, Limoges, France

[2] Hop Timone Enfants, AP HM, CRCM Pediat Marseille, Marseille, France

[3] Hosp Civils Lyon, Hop Femme Mere Enfant, CRCM Pediat Lyon, Lyon, France

[4] Univ Lyon, CNRS, UMR 5558, EMET,LBBE, Villeurbanne, France

来源：

CLINICAL CASE REPORTS | 2019年 / 7卷 / 04期

关键词：

azoles; cystic fibrosis; ivacaftor; lumacaftor; tacrolimus;

D O I：

10.1002/ccr3.2053

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Key Clinical Message We report the initiation of CFTR modulator lumacaftor/ivacaftor combination (LUM/IVA) in two adolescents with cystic fibrosis who were treated with antifungal azoles (AZO) and tacrolimus (TCS) for liver transplantation. Despite multiple drug-drug interactions, maintaining therapeutic TCS levels was achievable. During the following year, LUM/IVA was well tolerated, providing clinical benefits.

引用

页码：616 / 618

页数：3

共 5 条

[1]

(CHMP) CfMPfHU, 2006, EMA859972006 CHMP CF

[2]

E MA, 2015, Eur. Med. Agency, V44, P1

[3] Therapeutic challenges posed by critical drug-drug interactions in cystic fibrosis [J].

Jordan, Cameron L. ;

Noah, Terry L. ;

Henry, Marianna M. .

PEDIATRIC PULMONOLOGY, 2016, 51 :S61-S70

[4] CFTR modulator therapy in patients with cystic fibrosis and an organ transplant [J].

Mitchell, Ruth M. ;

Jones, Andrew M. ;

Barry, Peter J. .

PAEDIATRIC RESPIRATORY REVIEWS, 2018, 27 :6-8

[5] Determinants of the Magnitude of Interaction Between Tacrolimus and Voriconazole/Posaconazole in Solid Organ Recipients [J].

Vanhove, T. ;

Bouwsma, H. ;

Hilbrands, L. ;

Swen, J. J. ;

Spriet, I. ;

Annaert, P. ;

Vanaudenaerde, B. ;

Verleden, G. ;

Vos, R. ;

Kuypers, D. R. J. .

AMERICAN JOURNAL OF TRANSPLANTATION, 2017, 17 (09) :2372-2380

← 1 →